Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Price Target of $4.00 According to Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been assigned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $4.00.

A number of equities analysts have weighed in on the company. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. Finally, Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HOWL. Squarepoint Ops LLC bought a new position in Werewolf Therapeutics in the second quarter valued at $37,000. BlackRock Inc. acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $37,000. Vilga Financial Planning LLC acquired a new stake in Werewolf Therapeutics in the 3rd quarter valued at $49,000. Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics in the 3rd quarter valued at $55,000. Finally, Bank of America Corp DE bought a new stake in Werewolf Therapeutics during the 2nd quarter worth about $112,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

HOWL stock opened at $0.98 on Friday. The stock has a market capitalization of $47.63 million, a P/E ratio of -1.29 and a beta of 0.51. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $1.83. The business has a 50-day moving average of $0.92 and a 200-day moving average of $0.65.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million during the quarter, compared to analyst estimates of $21.00 million. Equities analysts expect that Werewolf Therapeutics will post -0.89 EPS for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.